91 patients with elbow fractures included in the PERK clinical trial study were included in this sub-group analysis comparing fracture healing, functional outcomes and adverse events between oral ketotifen fumarate treatment and placebo. Follow up was performed at 12 and 52 weeks. Results revealed no significant differences between the ketotifen fumarate and placebo groups in fracture healing, incidence of heterotopic ossification, DASH scores, and incidence of serious adverse events. Range of motion in the flexion-extension arc of the elbow was significantly favourable in the ketotifen fumarate group at 12 weeks.